Provided By GlobeNewswire
Last update: Mar 31, 2025
– FDA meeting to align on myositis registrational trial designs for rese-cel in 1H25 on track –
– Enrolling approximately one patient per week across the RESET™ clinical development program since ACR Convergence presentation in November 2024 with 33 patients enrolled across 56 active clinical trial sites in the U.S. & Europe as of March 14, 2025 –
Read more at globenewswire.com1.87
-0.04 (-2.09%)
Find more stocks in the Stock Screener
Discover the top movers in Friday's pre-market session and stay informed about market dynamics.
Traders are paying attention to the gapping stocks in Thursday's session. Let's dive into which stocks are experiencing notable gaps.